Keyphrases
Chronic Heart Failure
100%
Spironolactone
100%
Receptor Antagonism
100%
Angiotensin Receptor Blockade
100%
Aldosterone Receptor
100%
Reverse Remodeling
100%
Candesartan
60%
Moderate to Severe
40%
Left Ventricular Ejection Fraction
40%
Angiotensin Receptor Blockers
40%
Systolic Heart Failure
40%
Left Ventricular Remodeling
40%
Tissue Doppler Imaging
40%
Left Ventricular Mass
40%
Clinical Outcomes
20%
Beneficial Effects
20%
Heart Failure Patients
20%
Echocardiographic
20%
Left Ventricular Function
20%
Severe Heart Failure
20%
Left Ventricular Volume
20%
Chronic Systolic Heart Failure
20%
Peak Systolic Velocity
20%
Left Ventricular End-diastolic Volume (LVEDV)
20%
Placebo Control Groups
20%
Volume Index
20%
Systolic Strain
20%
Cyclic Variation
20%
Integrated Backscatter
20%
Filling Pressure
20%
End-systolic Volume
20%
Cardiac Magnetic Resonance Imaging (cMRI)
20%
Medicine and Dentistry
Congestive Heart Failure
100%
Angiotensin Receptor
100%
Receptor Blocking
100%
Aldosterone Receptor
100%
Spironolactone
100%
Candesartan
60%
Systolic Heart Failure
60%
Heart Left Ventricle Ejection Fraction
40%
Angiotensin Receptor Antagonist
40%
Tissue Doppler Imaging
40%
Placebo
20%
Heart Left Ventricle Function
20%
Carvedilol
20%
Cardiac Magnetic Resonance Imaging
20%
End-Systolic Volume
20%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Spironolactone
100%
Angiotensin Receptor
100%
Aldosterone Receptor
100%
Candesartan
60%
Systolic Heart Failure
60%
Angiotensin Receptor Antagonist
40%
Placebo
20%
Carvedilol
20%
Veterinary Science and Veterinary Medicine
Aldosterone
100%
Spironolactone
100%
Angiotensin
100%
Candesartan
60%
Ejection Fraction
40%
Tissue Doppler Imaging
40%
End-Systolic Volume
20%
Cardiac Magnetic Resonance Imaging
20%
Carvedilol
20%
Neuroscience
Angiotensin Receptor
100%
Spironolactone
100%
Aldosterone Receptor
100%
Candesartan
60%
Tissue Doppler Imaging
40%
Placebo
20%
Carvedilol
20%
Cardiac Magnetic Resonance Imaging
20%
End-Systolic Volume
20%